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a b s t r a c t
Discovering the mechanisms by which cell signaling controls the cell cycle of the human malaria parasite
Plasmodium falciparum is fundamental to designing more effective antimalarials. To better understand
the impacts of melatonin structure and function on the cell cycle of P. falciparum, we have synthesized
two families of structurally-related melatonin compounds (7e11 and 12e16). All synthesized melatonin
analogs were assayed in P. falciparum culture and their antimalarial activities were measured by ﬂow
cytometry. We have found that the chemical modiﬁcation of the carboxamide group attached at C-3
position of the indole ring of melatonin (6) was crucial for the action of the indole-related compounds on
the P. falciparum cell cycle. Among the melatonin derivatives, only the compounds 12, 13 and 14 were
capable of inhibiting the P. falciparum growth in low micromolar IC50. These results open good per-
spectives for the development of new drugs with novel mechanisms of action.
 2014 Elsevier Masson SAS. All rights reserved.
1. Introduction
Annually, more than 300 million people are infected by the
Plasmodium protozoan, the etiological agent of malaria and
approximately one million people are expected to die each year
according to the World Health Organization (WHO). Whereas
chemotherapy has previously been quite successful in the treat-
ment of malaria, the Plasmodium parasite currently exhibits an
increased resistance to classical antimalarials, hastening the search
for new compounds [1].
Examples of drugs used clinically in the treatment of malaria
include doxycycline (1), a synthetically derived tetracycline anti-
biotics group, and quinone-related compounds (2e5) (Fig. 1).
Speciﬁc treatment options depend on the species of malaria para-
site causing the infection, the part of the world in which the
infection was acquired, pregnancy status, and the severity of
infection.
Our knowledge of the basic biology that underlies the Plasmo-
dium development through the stages ring, trophozoite and
schizont within the red blood cells (RBCs) is still limited. Therefore,
it is important to identify compounds that modulate the RBC stages
of the malaria life cycle. Melatonin (N-acetyl-5-methoxytryptamine,
6) is a tryptophan-derived hormone that participates in several
physiological activities that are inﬂuenced by the light/dark circa-
dian cycle [2]. It is secreted by the pineal gland of all mammals and is
also present in plants [2e8]. The effects on Plasmodium cell cycle
were ﬁrstly described by Hotta and collaborators in a work that
demonstrated that the synchronization of parasite development is
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lost in pinealectomized mice, but restored when melatonin were
administrated [5]. The effects ofmelatonin in Plasmodium falciparum
were extensively evaluated in several works [9e11] and include a
complex signaling pathway. The molecular mechanism for mela-
tonin action in P. falciparum and Plasmodium chabaudi is quite
complex and includes an increase in cytosolic calcium and cAMP
and activation of proteases and PKA [6,8,12,13]. Second messengers
play a fundamental role in different biological systems that activate
a myriad of cellular components including protozoan [14e19].
Several laboratories have investigated the role of calcium and cAMP
in malaria parasite cycle as well as potential molecular targets
including kinases and proteases [12,20e24]. For P. falciparum
melatonin triggers IP3 generation [25], protease activation [12] and
activate a subset of genes for the ubiquitin proteasome-system (UPS)
[26]. Recently, we found that the P. falciparum transcription factor, Pf
NF-YB is modulated by melatonin [27].
In addition to melatonin, its precursor N-acetylserotonin, sero-
tonin, tryptamine, also affect parasite cell cycle [2]. In other way,
another indole compound, IAA (indole 3-acetic acid) that plays an
important role in physiological process of plants were unable to
modulate the cell cycle of P. falciparum or regulate the UPS genes as
observed for melatonin, indicating some level of speciﬁcity of
tryptophan compounds on Plasmodium cell cycle control [28].
Melatonin (6) has a central role in the control of parasite
replication and establishment of parasitemia, so targeting and
blocking this hormone pathway can contribute to the discovery of
new antimalarial drugs. Bagnaresi and collaborators have shown
that when parasite’s synchronicity is disrupted by the addiction of
the melatonin receptor blocker Luzindole, the antimalarial activity
of chloroquine is enhanced at suboptimal doses [29]. Increased
resistance to classical antimalarials urges the discovery of new
compounds that can be used in the clinical arsenal against malaria.
Our interest in the development of new melatonin antagonists
prompted us to synthesize and test the ability of new melatonin-
related compounds 7e11 and 12e16 to modulate the human ma-
laria parasite cell cycle and block parasite’s development acting as
antimalarials. These N-heterocyclic derivatives were designed by
molecular modiﬁcations in the structure of the lead compound
melatonin, as shown in Scheme 1. The hydrogen substitution on the
methoxy group and the introduction of the different substituents
attached to the carboxamide at the C-3 position of the indole ring of
melatonin resulted in family 7e11. In the second family, we have
investigated the substitution pattern of the amide function (for
compounds 12e15) and presence of a primary amine group (for
compound 16) attachment to the indole system of melatonin on the
cell cycle of P. falciparum (Scheme 1).
2. Results and discussion
2.1. Chemistry
The compounds 7e11 and 12e16 were prepared according to
the synthetic pathways described in Scheme 2. Tryptamine (17)
was reactedwith acetic anhydride to give the N-acetyl compound 7.
The two series of indole derivatives 8e10 and 12e14 were
synthesized by N-acylation reaction of tryptamine (17) or 5-
methoxytryptamine (16) with the appropriate acyl chloride.
Finally, the compounds 17 and 16 were easily converted into the
corresponding carbamate derivatives 11 and 15, on treatment with
methyl chloroformate an aqueous solution of NaOH at 0 C [30e33].
2.2. Effect of two families of indole derivatives 7e11 and 12e16 on
cell cycle of P. falciparum
Melatonin and its derivatives control P. falciparum and
P. chabaudi cell cycle [2,4,7]. Given that the potential role of mela-
tonin derivatives and despite the chemical compounds here tested
were already knew, we followed their ability to block the human
malaria parasite P. falciparum cell cycle. To interfere with signaling
pathways and parasite replication inside RBCs we next investigated
the synthetic melatonin derivatives and search for their potential
pharmacological activity. The two series of synthetic indole com-
pounds 7e11 and 12e16were incubatedwith P. falciparum-infected
using different combination as well as alone cell for their in vitro
antimalarial activity.
After compounds incubation in the culture, we assess their ac-
tion by following parasitemia using ﬂow cytometry and the DNA-
bindingﬂuorescent dye YOYO-1 [34].When compared to the control
(solvent treated), the following compounds signiﬁcantly increased
parasitemia: (6) 21.9  0.8% (p < 0.001), (7) 12.9  4.6 (p < 0.001);
(8) 9.2  3.1 (p < 0.05) and (11) 11.7  5 (p < 0.01), (14) 10.8  3%
(P< 0.01), (15) 10 2% (p< 0.05) and (16) 19.7 5.2 (p< 0.001). The
other compounds showed no signiﬁcant increase in parasitemia
compared to control: (9) 6  4.8, (10) 5.3  2.2%, (12) 8  2.6%, (13)
7.8  1%, as shown in Fig. 2. Among the compounds tested, only 16
showed an increase of parasitemia similar to melatonin.
The change of a methoxy substituent attachment to the indole
ring of melatonin (e.g. 7e11) caused a decrease in themodulation of
cell cycle of P. falciparum, showing an important function of this
radical in the indole cellular responses. In the same way, the chain
elongation of the amino functional group (8e10) decreases the
reactivity of this compound in the cell cycle of P. falciparum. The
presence of a carbamate moiety (11) at the C-3 position of the
Fig. 1. Some examples of drug used clinically in the treatment of malaria.
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Scheme 2. Synthesis of two families of indole derivatives 7e11 and 12e16.
Scheme 1. Structural analogy between melatonin and indole derivatives 7e11 and 12e16.
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indole ring resulted lower effect on parasite cycle when compared
to 7 and melatonin (6).
The compounds structurally related to melatonin 12e14 pre-
sented a signiﬁcantly lower effect on parasite cycle when compared
to melatonin, suggesting a decrease in potency of these ligands due
to bulky side chains at the C-3 position of the indole ring.
Among structurally related compounds studied, 16 induced an
increase in parasitemia similar to the melatonin effect on
P. falciparum cycle (19.7  5.2%). This compound differs from
melatonin structure by absence of the acetyl group at the C-3 po-
sition of the indole system. The active biological proﬁle of this
compound is probably due to number of hydrogen acceptors of the
amine group.
These results are consistent with those of Sugden et al. (1997),
which evaluated the afﬁnity of different compounds with a struc-
ture based on melatonin with modiﬁcations at the radical’s
methoxy and N-acyl in Xenopus leavis melanophores, Cos-7 and
NIH 3T3. The removal of the group 5-methoxy or N-acyl led to a
reduced in the receptor binding afﬁnity in all compounds. The
addition of up to two carbons in the N-acyl side chain retained the
binding afﬁnity of the compounds to receptors MT1/MT2/MT3, but
longer chains with 4e5 carbons signiﬁcantly reduced the binding
afﬁnity. Such modiﬁcations performed by Sugden et al. (1997) are
similar to those modiﬁcations made at 9 and 13 which similarly
exhibited a reduced response to P. falciparum compared to the ef-
fect of melatonin on parasite cycle (Fig. 2).
We next have incubated the compounds 7e11 and 12e16 along
with the hormone melatonin (6) in an asynchronous culture of
P. falciparum 3D7 to investigate their potential ability to interfere
with melatonin effect on P. falciparum cell cycle acting as an in-
hibitor of the hormone effect. After 48 h of incubation the para-
sitemia was checked by ﬂow cytometry. Compared with the control
(solvent) the following compounds signiﬁcantly increased the
parasitemia: (6) 23.5  6.8% (p < 0.0001), (15) 14.5  5.8% (p < 0,
05) and (16) 14.1  2.4% (p < 0.05). The other compounds showed
no signiﬁcant increase in parasitemia compared to control: (12)
8.8  4.2%, (13) 8.6  3.2%, (14) 9.1  3.4%, (7) 11.3  6, 8%, (8)
116.9%, (9) 6.9 3%, (10) 6.7 2.6% and (11) 10.9 4.1% as shown
in Fig. 3. These compounds (7e11) and (12e14) were able to inhibit
the effect of melatonin (6) in the parasite by acting as blockers of
the modulation induced by hormone.
From the analysis of the structures we can conclude that an
increase in the number of carbon atoms in structures of 9,10,12 and
13 has a deleterious effect on cell cycle modulation, even keeping
the methoxy group at position 50. Furthermore, as also veriﬁed by
other works [35e40], we note that themethoxy group at position 50
plays an important role for the activity of melatonin on its receptor,
since the compounds that do not present this group (7e11)
generally presents a minor effect on parasitemia (Fig. 2). Although
the importance of the methoxy group 50 on the receptor activity,
this radical is not essential for the compound binding, as com-
pounds lacking the methoxy 50group were capable of inhibit the
melatonin effect on the cell cycle progression of parasite (Fig. 3).
2.3. Antimalarial activity of compounds 12e14
Among the indole analogues of two series 7e11 and 12e16,
compounds 12,13 and 14 showed potential antimalarial activity.We
performed a doseeresponse curve to obtain the IC50 value of these
compounds using ring-stage synchronized parasites. The com-
pounds showed the following IC50: (12) (IC50 ¼ 19.17  0.08 mM),
(13) (IC50 ¼ 19.10  0.09 mM) and (14) (IC50 ¼ 2.93  0.064 mM)
(Fig. 4).
There are currently no available drugs of the class of indole
derivatives for the treatment of malaria. NITD609 is proposed as a
new antimalarial compounds belonging to the spiroindolone class
and showed IC50 ¼ 10 nM in the P. falciparum cycle and was able to
interfere with the transmission of the parasite to the vector
Anopheles [41]. This compound is currently in phase I of clinical
trials as an antimalarial. Besides this compound, other indolic
compounds presented antimalarial activity [42,43], at low micro-
molar concentration, ranging between 39 mM and 0.65 mM, similar
results obtained in this work, IC50 range of 19 to 2.9 mM. These
result shown the importance of indole nucleus for the development
of a new class of antimalarial.
The development of a new drugs class that act through different
mechanisms of action it is of great importance to circumvent the
increasing resistance of P. falciparum to existing antimalarials.
Accordingly, the description of three novel indole with very sig-
niﬁcant antimalarial activity opening good perspectives for devel-
opment of new drugs with novel mechanisms of action.
3. Experimental protocols
The chemical reagents and all solvents used in this study were
purchased from Merck AG (Darmstadt, Germany) and VETEC LTDA
(Rio de Janeiro, Brazil). Melatonin was purchased from Sigmae
Aldrich Brazil LTDA (São Paulo, Brazil).
Melting points were determined with a FishereJohns instru-
ment and are uncorrected. Infrared (IR) spectra were recorded on
an ABB FTLA2000-100 spectrophotometer in KBr pellets (Quebec,
Fig. 2. Effect of indole derivatives 7e11 and 12e16 (concentration 500 nM) on cell
cycle of P. falciparum. After incubation for 48 h the parasitemia was measured by ﬂow
cytometry. The data represent the percentage of parasitemia compared to control
(solvent treatment). (*) One-way ANOVA (***p < 0.001, **p < 0.01, *p < 0.05).
Fig. 3. Effect of indole derivatives on melatonin action in the P. falciparum cell cycle.
Compounds 7e11 and 12e16 (concentration 500 nM) were incubated along with 6
(100 nM) for 48 h. The parasitemia was measured by ﬂow cytometry. The data
represent the percentage of parasitemia compared to control (solvent). (*) One-way
ANOVA (**p < 0.001, *p < 0.05).
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Canada). NMR spectra, unless otherwise stated, were obtained in
deuterated Me2SO-d6 using a Varian Unity Plus 300 MHz spec-
trometer. Chemical shifts (d) are expressed in ppm and the coupling
constant (J) in Hertz. Reactions were routinely monitored by thin
layer chromatography (TLC) on silica gel pre-coated F254 Merck
plates. Column chromatography was performed on silica gel ﬂash
from Across. The developed chromatograms were viewed under
ultraviolet light at 254 nm.
The compound 16 has been synthesized using Venkatachalam
and co-workers protocol [31].
3.1. Chemistry
3.1.1. General procedure for the preparation of the melatonin
derivatives 8e10 and 12e14
An aqueous solution of 4 M sodium hydroxide (1.2 mmol) was
added slowly to a stirred solution of tryptamine (17) (1.2 mmol, for
compounds 8e10) or 5-methoxytryptamine (16) (1.2 mmol, for
compounds 12e14) in dichloromethane (3 mL) at 0 C. After 5 min
of stirring at 0 C, the appropriate chloride derivative (1.2 mmol)
was added dropwise. The mixture was stirred for 5 min at 0 C and
then for 3 h at room temperature. H2O (20 mL) was added. The two
layers were separated, and the aqueous phase was extracted with
dichloromethane (3  20 mL). The organic layers were dried
(MgSO4) and evaporated under reduced pressure. The crude
product was puriﬁed by ﬂash column chromatography on silica gel.
Elution was made successively with ethyl acetate/hexane (1:1) to
give the desired compound.
3.1.1.1. N-(2-(5-methoxy-1H-indol-3-yl)ethyl)butanamide (12).
Obtained in 17% yield as a pale yellow solid; m.p. 104e105 C; IR
(KBr) nmax (cm1) 3382 (NeH); 1677 (C]O); 1H NMR (300 MHz,
CDCl3) d 0.91 (t, 3H, CH3, J ¼ 4.5 Hz); 1.63 (q, 2H, CH2, J ¼ 4.5 Hz);
2.09 (t, 2H, CH2, J ¼ 4.5 Hz); 2.93 (t, 2H, CH2, J ¼ 4.5 Hz); 3.59 (t, 2H,
CH2, J ¼ 4.5 Hz); 3.85 (s, 3H, OCH3); 6.85e6.87 (m, 1H, H-30); 6.97e
6.98 (m, 1H, H-50); 7.03e7.04 (m, 1H, H-20); 7.24e7.28 (m, 1H, H-2);
8.56 (bs, 1H, NeH) ppm. 13C NMR (75MHz, CDCl3) d 13.6 (CH3); 19.1
(CH2); 25.3 (CH2); 38.7 (CH2); 39.6 (CH2); 55.9 (CH3); 100.4 (CH);
112.0 (CH); 112.3 (C); 122.9 (CH); 127.6 (C); 131.6 (C); 153.8 (C);
173.1 (C]O) ppm.
3.1.1.2. N-[2-(5-methoxy-1H-indol-3-yl)ethyl]hexanamide (13).
Obtained in 92% yield as a pale yellow solid; m.p. 71e72 C; IR (KBr)
nmax (cm1) 3319 (NeH); 1679 (C]O); 1H NMR (300 MHz, CDCl3)
d 0.88 (t, 3H, CH3, J ¼ 4.2 Hz); 1.22e1.29 (m, 4H); 1.58e1.61 (m, 2H,
CH2); 2.58e2.61 (m, 2H, CH2); 2.97e3.00 (m, 2H, CH2); 3.86 (s, 3H,
OCH3); 3.93 (t, 2H, CH2, J ¼ 4.2 Hz); 6.86e6.88 (m, 1H, H-30); 6.97e
6.98 (m, 1H, H-50); 7.10e7.11 (m, 1H, H-2); 7.24e7.28 (m, 1H, H-20);
7.90 (bs, 1H, NeH) ppm. 13C NMR (75MHz, CDCl3) d 13.9 (CH3); 22.4
(CH2); 24.6 (CH2); 25.1 (CH2); 31.3 (CH2) 37.9 (CH2); 44.9 (CH2); 55.9
(CH3); 100.4 (CH); 111.9 (CH); 112.1 (C); 112.4 (CH); 123.1 (CH);
127.6 (C); 131.4 (C); 154.2 (C); 176.5 (C]O) ppm.
3.1.1.3. N-[2-(5-methoxy-1H-indol-3-yl)ethyl]benzamide (14).
Obtained in 28% yield as a pale yellow solid; m.p. 107e109 C; IR
(KBr) nmax (cm1) 3299, 3059 (NeH); 1635 (C]O); 1H NMR
(300 MHz, CDCl3) d 2.98 (t, 3H, CH2, J ¼ 4.2 Hz); 3.69 (s, 3H, OCH3);
3.71e3.72 (m, 2H, CH2); 6.64e6,65 (m, 1H, H-30); 6.78e6.80 (m, 1H,
H-50); 6.88e6.89 (m,1H, H-20); 7.00e7.01 (m,1H, NH); 7.15e7.16 (m,
1H, H-2); 7.26e7.29 (m, 2H, H-300 and H-500); 7.36e7.39 (m, 1H, H-
400); 7.64e7.65 (m, 2H, H-200 and H-600); 8.75 (bs, 1H, NH) ppm. 13C
NMR (75 MHz, CDCl3) d 25.6 (CH2); 41.2 (CH2); 55.7 (CH3); 100.3
(CH); 111.9 (CH); 112.0 (CH); 122.2 (C); 122.9 (CH); 127.5 (C); 131.5
(C); 153.7 (C); 157.1 (C]O) ppm.
Fig. 4. Doseeresponse curve with different concentrations used to calculate the IC50 of the compounds 12 (a), 13 (b) and 14 (c) after 48 h incubation with P. falciparum.
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3.1.1.4. N-[2-(1H-indol-3-yl)ethyl]butanamide (8). Obtained in 34%
yield as a pale yellow solid; m.p. 84e86 C; IR (KBr) nmax (cm1)
3406, 3300 (NeH); 1645 (C]O); 1H NMR (300 MHz, CDCl3) d 0.91
(t, 3H, CH3, J ¼ 7.3 Hz); 1.62 (q, 2H, CH2, J ¼ 7.3 Hz); 2.09 (t, 2H, CH2,
J ¼ 7.3 Hz); 2.98 (t, 2H, CH2, J¼ 6.3 Hz); 3.61 (t, 2H, CH2, J ¼ 6.3 Hz);
5.59 (bs, 1H, NeH); 7.03e7.04 (m,1H, H-30); 7.11e7.14 (m,1H, H-40);
7.19e7.22 (m, 1H, H-20); 7.36e7.38 (m, 1H, H-2), 7.59e7.61 (m, 1H,
H-50); 8.15 (bs, 1H, NeH) ppm. 13C NMR (75 MHz, CDCl3) d 13.6
(CH3); 19.1 (CH2); 25.3 (CH2); 38.7 (CH2); 39.6 (CH2); 111.3 (CH);
112.6 (C); 118.5 (CH); 119.2 (CH); 122.1 (CH); 127.2 (C); 136.4 (C);
173.1 (C]O) ppm.
3.1.1.5. N-[2-(1H-indol-3-yl)ethyl]hexanamide (9). Obtained in 34%
yield as a pale yellow solid; m.p. 90e92 C; IR (KBr) nmax (cm1)
3397, 3256 (NeH); 1631 (C]O); 1H NMR (300MHz, CDCl3) d 0.87 (t,
3H, CH3, J ¼ 7.3 Hz); 1.23e1.30 (m, 4H); 1.55e1.61 (m, 2H, CH2);
2.08e2.11 (m, 2H, CH2); 2.96e2.98 (m, 2H, CH2); 3.61 (t, 2H, CH2,
J ¼ 6.3 Hz); 5.59 (bs, 1H, NeH); 7.03e7.04 (m, 1H, H-30); 7.11e7.14
(m,1H, H-40); 7.19e7.22 (m,1H, H-20); 7.37e7.38 (m,1H, H-2), 7.59e
7.61 (m, 1H, H-50); 8.17 (bs, 1H, NeH) ppm. 13C NMR (75 MHz,
CDCl3) d 13.8 (CH3); 22.3 (CH2); 25.2 (CH2); 31.3 (CH2) 36.3 (CH2);
39.6 (CH2); 111.2 (CH); 112.7 (C); 118.5 (CH); 119.3 (CH); 122.0 (CH);
127.2 (C); 136.4 (C); 173.3 (C]O) ppm.
3.1.1.6. N-[2-(1H-indol-3-yl)ethyl]benzamide (10). Obtained in 52%
yield as a pale yellow solid; m.p. 130e132 C; IR (KBr) nmax (cm1)
3406, 3300 (NeH); 1645 (C]O); 1H NMR (300MHz, CDCl3) d 3.11 (t,
3H, CH2, J¼ 6.3 Hz); 3.81 (q, 2H, CH2, J¼ 6.3 Hz); 6.33 (bs,1H, NeH);
7.04e7.07 (m, 1H, H-30); 7.11e7.16 (m, 1H, H-40); 7.19e7.24 (m, 1H,
H-20); 7.35e7.40 (m, 3H, H-2, H-50 and H-300); 7.44e7.49 (m, 1H, H-
500); 7.64e7.68 (m, 3H, H-200, H-400 and H-600); 8.31 (bs, 1H, NeH)
ppm. 13C NMR (75 MHz, CDCl3) d 25.2 (CH2); 40.2 (CH2); 111.3 (CH);
112.9 (C); 118.7 (CH); 119.5 (CH); 122.1 (CH); 122.2 (CH); 126.8
(CH); 127.3 (C); 128.5 (CH); 131.3 (CH); 134.6 (C); 136.4(C) ppm.
3.1.1.7. N-(2-(1H-indol-3-yl)ethyl)acetamide (7). A solution of ace-
tic anhydride (0.3 mL, 0.318 mmol) and triethylamine (0.52 mL,
3.74 mmol) in CH2Cl2 (1 mL) was added dropwise to a stirred
suspension of tryptamine (17) (0.3 g, 1.87 mmol) in dry CH2Cl2
(4.5 mL). After 10 min of stirring at room temperature, the reaction
mixturewas treatedwith a saturated aqueous NaHCO3 solution, the
organic layer was separated, and the aqueous layer was extracted
with CH2Cl2. The organic phase was washed with brine, dried with
MgSO4, and concentrated under reduced pressure. Puriﬁcation by
column chromatography using CHCl3:CH3OH (95:5) afforded
compound 7 (370 mg, 98%) as a pale yellow solid: 78e79 C; IR
(KBr) nmax (cm1) 3397, 3257 (NeH); 1631 (C]O); 1H NMR
(300 MHz, CDCl3) d 1.92 (s, 3H, CH3); 2.97 (t, 2H, CH2, J ¼ 7.2 Hz);
3.60 (t, 2H, CH2, J¼ 7.2 Hz); 5.73 (bs,1H, NeH); 7.03e7.04 (m,1H, H-
30); 7.10e7.15 (m, 1H, H-40); 7.18e7.23 (m, 1H, H-20); 7.36e7.39 (m,
1H, H-2), 7.58e7.61 (m, 1H, H-50); 8.22 (bs, 1H, NeH) ppm. 13C NMR
(75 MHz, CDCl3) d 23.1 (CH3); 25.1 (CH2); 39.9 (CH2); 111.3 (CH);
112.7 (C); 118.5 (CH); 119.3 (CH); 122.1 (CH); 127.3 (C); 136.4 (C);
170.3 (C]O) ppm.
3.1.2. General procedure for the preparation of the melatonin
derivatives 11 and 15
Methyl chloroformate (0.0597 mL, 0.624 mmol) and an aqueous
solution of NaOH (0.156 mL, 4 M, 0.624 mmol) were added to a
solution of tryptamine (17) (0.100 g, 0.624 mmol) or 5-
methoxytryptamine (16) (0.118 g, 0.624 mmol) in CHCl3 (1.56 mL)
at 0 C. The mixture was then stirred for 3 h at room temperature
and washed with water (1.5 mL). The aqueous phase was extracted
with dichloromethane (2  1.5 mL), and the combined organic
layers were dried (MgSO4) and evaporated under reduced pressure
to give orange oil. The crude product was puriﬁed by ﬂash column
chromatography on silica gel. Elution was made successively with
ethyl acetate/hexane (1:1) to give the desired compound.
3.1.2.1. Methyl [2-(5-methoxy-1H-indol-3-yl)ethyl]carbamate (15).
Obtained in 57% yield as a pale yellow solid; m.p. 76e77 C; IR
(KBr) nmax (cm1) 3322 (NeH); 1670 (C]O); 1H NMR (300 MHz,
CDCl3) d 2.81 (t, 2H, CH2, J ¼ 6.6 Hz); 3.38e3.39 (m, 2H, CH2); 3.55
(s, 3H, CH3); 3.74 (s, 3H, OCH3); 6.73e6.77 (m, 1H, H-30); 6.82e
6.83 (m, 1H, H-50); 6.92e6.93 (m, 1H, H-20); 7.10e7.12 (m, 1H, H-2);
8.29 (bs, 1H, NeH) ppm. 13C NMR (75 MHz, CDCl3) d 25.6 (CH2);
41.2 (CH2); 51.9 (CH3); 55.8 (CH3); 100.3 (CH); 111.9 (CH); 112.0
(CH); 112.2 (C); 122.9 (CH); 127.5 (C); 131.5 (C); 153.7 (C); 157.1
(C]O) ppm.
3.1.2.2. Methyl [2-(1H-indol-3-yl)ethyl]carbamate (11).
Obtained in 68% yield as a pale yellow solid; m.p. 66e67 C; IR (KBr)
nmax (cm1) 3398, 3283 (NeH); 1688 (C]O); 1H NMR (300 MHz,
CDCl3) d 2.97 (t, 3H, CH2, J¼ 6.8 Hz); 3.51e3.52 (m, 2H, CH2); 3.66 (s,
3H, CH3); 4.75 (bs, 1H, NeH); 7.03e7.04 (m, 1H, H-30); 7.11e7.14 (m,
1H, H-40); 7.19e7.22 (m, 1H, H-20); 7.36e7.38 (m, 1H, H-2), 7.59e
7.61 (m, 1H, H-50); 8.06 (bs, 1H, NeH) ppm. 13C NMR (75 MHz,
CDCl3) d 25.7 (CH2); 41.2 (CH2); 51.9 (CH3); 111.1 (CH); 112.7 (C)
118.6 (CH); 119.3 (CH); 122.0 (CH); 122.0 (CH); 127.2 (C); 136.4 (C);
157.1 (C]O) ppm.
3.2. Biological evaluation
3.2.1. P. falciparum (3D7) in vitro culture
Parasites were cultured according to the method of Trager and
Jensen and were synchronized according to the method of Lambros
[44,45]. Brieﬂy, parasites were routinely maintained in Oþ human
erythrocytes (parasitaemia: 5%, hematocrit: 2%) in RPMI-1640
media supplemented with 0.21% sodium bicarbonate, 50 mg/L
hypoxanthine and 10% Oþ human serum in a 92% N2, 5% CO2, and 3%
O2 atmosphere.
3.2.2. Flow cytometry analysis
Infected erythrocytes were incubated with 500 nM of the
test compounds (7e11 and 12e16) and 100 nM of melatonin
(6) for 48 h and then ﬁxed in 2% paraformaldehyde in
phosphate-buffered saline (PBS) for 24 h; permeabilized and
stained with 0.1% Triton X-100 and 5 nM YOYO-1 (Molecular
Probes) incubated for 30 min at 37 C. Parasitemia was deter-
mined from dot plots (side scatter versus ﬂuorescence) of
105 cells acquired on a FACSCalibur ﬂow cytometer using
CELLQUEST software (Becton Dickinson). Initial gating was car-
ried out with unstained, uninfected erythrocytes to account for
erythrocyte autoﬂuorescence.
In the experiments of doseeresponse curves the compounds
12e14 were incubated with infected erythrocytes at the ring stage
with different concentrations of the compounds: 5 nM, 15 nM,
45 nM, 137 nM, 411 nM, 1.23 mM, 3.70 mM, 11.11 mM, 33.33 mM and
100 mM and incubated for 48 h. The following ﬂow cytometry were
performed as described above.
3.2.3. Statistics
Analyses of parasitemia were performed by a one-way analysis
of variance test followed by post hoc analysis by the Dunnett’s
Multiple Comparison Test using GraphPad Prism software. IC50
values were produced using sigmoid doseeresponse curves on
GraphPad software. At least three independent experiments were
performed for each assay.
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4. Conclusions
In summary, two series of 2-(indol-3-yl)ethylamine derivatives
7e11 and (2-(5-methoxy-1H-indol-3-yl)ethyl)amine derivatives
12e16 have been evaluated for their antimalarial activity against P.
falciparum (3D7) in vitro culture.
We tested the ability of these compounds to modulate the cycle
of the parasite, similarly to melatonin (6), as well assessed the
ability of these compounds to block the effect of the hormone on
cell cycle of P. falciparum, acting as inhibitors. Compounds 9 and 10
shown promising results, not being able to modulate cycle of the
parasite but being able to block the effect of melatonin in
Plasmodium.
Compounds 12e14 are promising lead structures for the
development of new derivatives with antimalarial activity. We are
currently working with these compounds to increase their activ-
ities, in particular by introducing structural changes at position N-1
of the indole ring.
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